CMPX Compass Therapeutics, Inc.
P/E
--
Forward P/E
--
Price/Sales
269.28
Beta
0.914
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Compass Therapeutics Receives Nasdaq Deficiency Notice Over $1.00 Bid Price Rule
Compass Therapeutics, Inc. (CMPX) disclosed it received a deficiency letter from Nasdaq on November 19, 2026, for failing to maintain a minimum bid price of...
Compass Therapeutics Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 11, 2026
Compass Therapeutics is expected to report a Q3 2026 loss of $0.12 per share on consensus revenue of $0.23 million, with its $0.84 current price trading well...
Compass Therapeutics third quarter 2026 loss widened to $27M during tovecimig BLA preparation
Compass Therapeutics reported a net loss of $27.2 million for the third quarter of 2026, driven by significantly higher manufacturing and pre-commercialization...
Compass Therapeutics Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
For the third quarter of 2026, analysts anticipate Compass Therapeutics will report a consensus revenue of $0.23 million and an earnings per share loss of...